Taylor RP[au] - Search Results

Year	Number of Results
1968	1
1969	2
1970	1
1973	2
1975	2
1976	3
1977	5
1978	4
1979	3
1980	4
1981	7
1982	1
1983	2
1984	6
1985	3
1986	3
1987	6
1988	1
1989	5
1990	2
1991	3
1992	9
1993	7
1994	9
1995	7
1996	3
1997	6
1998	2
1999	7
2000	4
2001	13
2002	8
2003	8
2004	8
2005	10
2006	11
2007	13
2008	12
2009	7
2010	6
2011	11
2012	9
2013	9
2014	10
2015	7
2016	9
2017	8
2018	4
2019	8
2020	8
2021	5
2022	0

1

Complement is activated by IgG hexamers assembled at the cell surface.

Diebolder CA, Beurskens FJ, de Jong RN, Koning RI, Strumane K, Lindorfer MA, Voorhorst M, Ugurlar D, Rosati S, Heck AJ, van de Winkel JG, Wilson IA, Koster AJ, Taylor RP, Saphire EO, Burton DR, Schuurman J, Gros P, Parren PW. Diebolder CA, et al. Among authors: taylor rp. Science. 2014 Mar 14;343(6176):1260-3. doi: 10.1126/science.1248943. Science. 2014. PMID: 24626930 Free PMC article.

2

Study Design and Rationale for the Phase 3 Clinical Development Program of Enobosarm, a Selective Androgen Receptor Modulator, for the Prevention and Treatment of Muscle Wasting in Cancer Patients (POWER Trials).

Crawford J, Prado CM, Johnston MA, Gralla RJ, Taylor RP, Hancock ML, Dalton JT. Crawford J, et al. Among authors: taylor rp. Curr Oncol Rep. 2016 Jun;18(6):37. doi: 10.1007/s11912-016-0522-0. Curr Oncol Rep. 2016. PMID: 27138015 Free PMC article. Review.

3

Mechanisms of Complement-Mediated Damage in Hematological Disorders.

Taylor RP, Lindorfer MA. Taylor RP, et al. Semin Hematol. 2018 Jul;55(3):118-123. doi: 10.1053/j.seminhematol.2018.02.003. Epub 2018 Feb 14. Semin Hematol. 2018. PMID: 30032747 Review.

4

Exercise-induced cardioprotection: endogenous mechanisms.

Starnes JW, Taylor RP. Starnes JW, et al. Among authors: taylor rp. Med Sci Sports Exerc. 2007 Sep;39(9):1537-43. doi: 10.1249/mss.0b013e3180d099d4. Med Sci Sports Exerc. 2007. PMID: 17805086 Review.

5

Null donors favor prepared immunologists.

Taylor RP. Taylor RP. Blood. 2019 Mar 28;133(13):1389-1390. doi: 10.1182/blood-2019-01-898775. Blood. 2019. PMID: 30923104 Free article. No abstract available.

6

The Role of Complement in the Mechanism of Action of Therapeutic Anti-Cancer mAbs.

Golay J, Taylor RP. Golay J, et al. Among authors: taylor rp. Antibodies (Basel). 2020 Oct 28;9(4):58. doi: 10.3390/antib9040058. Antibodies (Basel). 2020. PMID: 33126570 Free PMC article. Review.

7

How Do mAbs Make Use of Complement to Kill Cancer Cells? The Role of Ca².

Taylor RP, Lindorfer MA. Taylor RP, et al. Antibodies (Basel). 2020 Sep 4;9(3):45. doi: 10.3390/antib9030045. Antibodies (Basel). 2020. PMID: 32899722 Free PMC article. Review.

8

Antigenic modulation and rituximab resistance.

Taylor RP, Lindorfer MA. Taylor RP, et al. Semin Hematol. 2010 Apr;47(2):124-32. doi: 10.1053/j.seminhematol.2010.01.006. Semin Hematol. 2010. PMID: 20350659 Free PMC article. Review.

9

Neutrophils: positive or negative?

Taylor RP. Taylor RP. Blood. 2017 May 11;129(19):2596-2597. doi: 10.1182/blood-2017-03-774695. Blood. 2017. PMID: 28495923 Free article. No abstract available.

10

Special Issue: The Role of Complement in Cancer Immunotherapy.

Taylor RP. Taylor RP. Antibodies (Basel). 2021 Jul 23;10(3):29. doi: 10.3390/antib10030029. Antibodies (Basel). 2021. PMID: 34449550 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results